IMR Press / RCM / Volume 25 / Issue 1 / DOI: 10.31083/j.rcm2501031
Open Access Review
Artificial Intelligence in the Screening, Diagnosis, and Management of Aortic Stenosis
Show Less
1 Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
2 Center for Structural Heart Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
*Correspondence: fuwaiwyj@163.com (Yongjian Wu)
Rev. Cardiovasc. Med. 2024, 25(1), 31; https://doi.org/10.31083/j.rcm2501031
Submitted: 31 July 2023 | Revised: 30 August 2023 | Accepted: 13 September 2023 | Published: 17 January 2024
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

The integration of artificial intelligence (AI) into clinical management of aortic stenosis (AS) has redefined our approach to the assessment and management of this heterogenous valvular heart disease (VHD). While the large-scale early detection of valvular conditions is limited by socioeconomic constraints, AI offers a cost-effective alternative solution for screening by utilizing conventional tools, including electrocardiograms and community-level auscultations, thereby facilitating early detection, prevention, and treatment of AS. Furthermore, AI sheds light on the varied nature of AS, once considered a uniform condition, allowing for more nuanced, data-driven risk assessments and treatment plans. This presents an opportunity to re-evaluate the complexity of AS and to refine treatment using data-driven risk stratification beyond traditional guidelines. AI can be used to support treatment decisions including device selection, procedural techniques, and follow-up surveillance of transcatheter aortic valve replacement (TAVR) in a reproducible manner. While recognizing notable AI achievements, it is important to remember that AI applications in AS still require collaboration with human expertise due to potential limitations such as its susceptibility to bias, and the critical nature of healthcare. This synergy underpins our optimistic view of AI’s promising role in the AS clinical pathway.

Keywords
aortic stenosis
artificial intelligence
screening
risk stratification
TAVR
surveillance
Graphical Abstract
View Full Image
Download
Funding
2020YFC2008103/National Key R&D Program of China
Figures
Fig. 1.
Share
Back to top